Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway

Receptor tyrosine kinase (RTK) inhibitors, such as sunitinib and sorafenib, remain the first-line drugs for the treatment of mRCC. Acquired drug resistance and metastasis are the main causes of treatment failure. However, in the case of metastasis Renal Cell Cancer (mRCC), which showed a good respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Luchao, Zhao, Shuo, Liu, Zhengfang, Zhang, Nianzhao, Pang, Shuo, Liu, Jikai, Liu, Cheng, Fan, Yidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910457/
https://www.ncbi.nlm.nih.gov/pubmed/33637706
http://dx.doi.org/10.1038/s41419-021-03511-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910457/
https://www.ncbi.nlm.nih.gov/pubmed/33637706
http://dx.doi.org/10.1038/s41419-021-03511-3

Ejemplares similares